Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795643 | 0.90 | MAPT (0.45) | MAPTCYP1A2RAB9ACYP2A6MAPK9 | |
| SCHEMBL1606348 | 0.84 | MAPT (0.67) | MAPTCYP1A2RAB9AKMT2AALDH1A1 | |
| SCHEMBL29496547 | 0.84 | MAPT (0.67) | MAPTCYP1A2RAB9AKMT2AALDH1A1 | |
| SCHEMBL29834220 | 0.84 | MAPT (0.67) | MAPTCYP1A2RAB9AKMT2AALDH1A1 | |
| SCHEMBL6401400 | 0.83 | RAB9A (0.49) | MAPTCYP1A2RAB9ACYP2A6TDP1 | |
| SCHEMBL7948363 | 0.83 | L3MBTL1 (0.43) | MAPTCYP1A2RAB9ATDP1KMT2A | |
| SCHEMBL7804747 | 0.83 | MAPT (0.59) | MAPTCYP1A2RAB9AKMT2AALDH1A1 | |
| SCHEMBL1305818 | 0.83 | CYP1A2 (0.46) | MAPTCYP1A2RAB9ACYP2A6KMT2A | |
| SCHEMBL29176 | 0.81 | MAPT (0.39) | MAPTCYP1A2RAB9ACYP2A6TDP1 | |
| SCHEMBL29361524 | 0.81 | MAPT (0.39) | MAPTCYP1A2RAB9ACYP2A6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1068386-A | — | — | None | — | — | JP | disclosed |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | KYOWA PHARMA CHEMICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3950672-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | Kyowa Pharma Chemical Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10710989-B2 | Method for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-14 | — | — | US | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20180079741-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9896402-B2 | Method for preventing decrease in optical purity | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| EP-0478147-B1 | Process for producing optically active gamma-butyrolactone derivatives | TAKASAGO PERFUMERY CO LTD (JP) | 1996-11-06 | — | — | EP | disclosed |
| US-5420306-A | Process for producing optically active γ-butyrolactone derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1995-05-30 | — | — | US | disclosed |
| US-5412109-A | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1995-05-02 | — | — | US | disclosed |
| US-5349107-A | Ruthenium optically active phosphine complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-09-20 | — | — | US | disclosed |
| EP-0592881-A2 | Process for producing optically active gamma-hydroxyketones | Takasago International Corporation (JP) | 1994-04-20 | — | — | EP | disclosed |
| EP-0580336-A1 | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-01-26 | — | — | EP | disclosed |
| US-5198562-A | Assymetric reactions | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1993-03-30 | — | — | US | disclosed |
| EP-0478147-A1 | Process for producing optically active gamma-butyrolactone derivatives | Takasago International Corporation (JP) | 1992-04-01 | — | — | EP | disclosed |
| EP-0470756-A2 | Ruthenium-phosphine complex useful as catalyst and intermediate for synthesis thereof | Takasago International Corporation (JP) | 1992-02-12 | — | — | EP | disclosed |
| JP-S6468386-A | 2,2'-BIS(DI-(P-METHOXYPHENYL)PHOSPHINO)-1,1'-BINAPHTHYL | TAKASAGO PERFUMERY CO LTD | 1989-03-14 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | PTGS1, PTGER1, RACK1 | MAPT 4859/4885CYP1A2 472/4885RAB9A 3323/4885 |
| US-10988469-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | MAPT 3660/4885CYP1A2 1113/4885RAB9A 1416/4885 |
| US-20180079741-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | DHPS, QDPR, DPYD | MAPT 3357/4885CYP1A2 28/4885RAB9A 3014/4885 |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | MAPT 3660/4885CYP1A2 1113/4885RAB9A 1416/4885 |
| US-10710989-B2 | Method for producing heterocyclic compound | APP, THOP1, TALDO1 | MAPT 16/4885CYP1A2 1870/4885RAB9A 4326/4885 |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | MAPT 3660/4885CYP1A2 1113/4885RAB9A 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.